We’re pleased for Adicet’s Head of Clinical Operations, Ekatherina Goryachikov to share best practices for designing and running a CAR T cell therapy in autoimmune and oncology indications during a featured session at the 5th Annual Gamma Delta T Cell Therapies Summit! As a track leader, she also facilitated a series of sessions on techniques to develop gamma delta T cells at a commercial scale. #CART #celltherapy #gammadelta #gammadeltaconference #clinicaltrials #autoimmune #autoimmuneclinicaltrials #cancerresearch #leadership #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf
About us
At Adicet (Nasdaq: ACET), we are defined by our mission to deliver best-in-class gamma-delta T cell therapies for patients fighting cancer. Every one of our team members, whether in the lab, manufacturing, or general business role, comes to work every day with the patient in mind. As pioneers in the cell therapy space, we are honored and humbled by the opportunity to put our talents to bear in developing transformative therapies to defeat cancer. We believe that the best way to do this is through discovering and developing allogeneic gamma-delta T cell therapies, a novel type of cell therapy. Adicet has chosen the gamma-delta T cell because it has multiple ways to target and kill cancer cells, which may provide a better chance of achieving complete and durable responses to therapy. Additionally, instead of using cells from the already sick cancer patient, Adicet uses cells from unrelated donors (allogeneic) because they are reliable and readily available allowing us to rapidly and cost-effectively scale production of these medicines and make them available when needed (“off-the-shelf”). Specifically, as a clinical stage biotechnology company we are advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL) to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. To learn more or inquire about joining our team in Boston, MA or Redwood City, CA, please visit http://www.adicetbio.com
- Website
-
http://www.adicetbio.com
External link for Adicet Bio, Inc
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Redwood City, California
- Type
- Public Company
Locations
-
Primary
Get directions
1000 Bridge Pkwy
Redwood City, California 94065, US
-
Get directions
200 Clarendon Street
6th Floor
Boston, MA 02116, US
Employees at Adicet Bio, Inc
Updates
-
Dr. Francesco Galimi, MD PhD, Adicet Chief Medical Officer, leads several sessions this week at the Gamma Delta T Cell Therapies Summit! Along with other C-suite execs, Dr. Galimi reflects on the industry advances and key insights from 2023 and anticipates the path ahead in 2024 via a review of the latest clinical updates, investor trends and opportunities for gamma delta T cells to drive solid tumor and autoimmune success. Tomorrow, he kicks off the conference after the Chair’s Opening Remarks with a Clinical Overview of Adicet’s lead product candidate ADI-001 in autoimmune diseases and cancer, then participates in a Fireside chat reviewing the unique promise of gamma delta T cell therapies for autoimmune diseases. #CART #celltherapy #gammadelta #gammadeltaconference #clinicaltrials #autoimmune #autoimmuneclinicaltrials #cancerresearch #leadership #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf
-
We’re honored for our Chief Medical Officer, Dr. Francesco Galimi, MD PhD and our Head of Clinical Operations, Ekatherina Goryachikov to have prominent and multiple speaking roles during the 5th Annual Gamma Delta T Cell Therapies Summit in Boston this week! With an advanced and broad #pipeline of gamma delta T cell therapies in development, our Adicet execs join other top thought leaders in the field to review how this promising approach aims to transform the treatment landscape for patients across a range of autoimmune and oncologic diseases. #CART #celltherapy #gammadelta #gammadeltaconference #clinicaltrials #autoimmune #autoimmuneclinicaltrials #cancerresearch #leadership #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf
-
-
We are pleased that ADI-270, the first ever #gammadelta 1 CAR T #celltherapy candidate to enter #clinicaltrials for solid tumors, has been granted Fast Track Designation by the FDA. First trial is in renal cell carcinoma, the most common type of kidney cancer. This significant milestone underscores our commitment to advancing innovative treatments to patients as quickly as possible. Check out the press release here: https://lnkd.in/gRUwpHPm #allogeneic #CART #TCellRx #celltherapy #renalcellcarcinoma #RCC #Research #clinicaltrial #clinicaltrials #cancer #oncology #biotechnology #biotech
-
-
In Our Week in Review… we’re excited about the IND clearance for ADI-270, the first ever #gammadelta 1 CAR T cell therapy candidate to enter clinical trials for the treatment of #solidtumors. The successful IND clearance of this #armored CD70-targeted CAR gamma delta T cell for the treatment of renal cell carcinoma is the result of our team’s deep commitment to advancing science on behalf of #patients. Many thanks to all at Adicet Bio, Inc who worked on this -- we look forward to seeing the continued progress of this program of behalf of the patients we serve. https://lnkd.in/gpB6pba5 #allogeneic #CART #TCellRx #celltherapy #renalcellcarcinoma #RCC #Research #clinicaltrial #clinicaltrials #cancer #oncology #biotechnology #biotech
-
-
Adicet Chief Scientific Officer Blake Aftab will serve as one of the top thought leaders at the 6th Annual Allogeneic Cell Therapies Summit! He’ll join the Industry Leaders Fireside Chat to review the latest advances in the allogeneic cell therapy space, celebrating this year’s significant wins and charting the strategy for continuing progress in #research and development moving forward. #allogeneic #celltherapy #CART #clinicaltrials #biotech #biotechnology
-
-
Adicet is pleased to announce that the FDA has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or IV lupus nephritis! The FDA’s decision to grant ADI-001 Fast Track Designation for lupus nephritis underscores the urgent need for new therapies for this chronic disease. Advancing #research is critical to the development of novel therapies for people living with #lupus. Learn more about Adicet’s #clinicaltrial in lupus nephritis at https://lnkd.in/esC4winc To see the full announcement, click here: https://lnkd.in/gmzbgGyj #celltherapy #gammadelta #CART #autoimmune #clinicaltrials #biotechnology #patientcare #clinicaltrialparticipation
-
Thank you to #LupusTherapeutics, Lupus Research Alliance and all attendees at this year's #LuCINCommunity Meeting. It's an honor to collaborate with this dedicated community of passionate researchers, industry peers and people with #lupus focused on a mission to ensure that all people with lupus receive equitable access to safe and effective therapies. #LupusAwarenessMonth #LupusClinicalResearch #autoimmune #gammadelta #celltherapy
-
-
We are pleased for our Chief Medical Officer, Francesco Galimi, MD PhD, to join other global thought leaders at the 1st International Autoimmune CAR T Innovators Summit this weekend in Grassau, Germany! We’re excited to exchange ideas among global CAR T experts through presentations on basic research, clinical studies, and case reports, to tackle the challenges facing the treatment of autoimmune diseases today. Exploring how CAR T cell therapy may help drive innovation, we’re applying our collective insights to create a paradigm shift in the treatment landscape to positively impact patients’ lives. #CART #autoimmune #celltherapy #gammadelta #innovation #leadership
-
-
Adicet is honored to support #WorldLupusDay! We stand with the #lupuscommunity and celebrate the progress being made in #LupusClinicalResearch. Today's discussions at the #LupusTherapeutics #LuCINCommunity Meeting around new approaches to cell therapy for autoimmune disease provide hope for the future of #lupus treatment. Participation in research and increasing access to #clinicaltrials is critical to the development of more effective therapies in #lupus. Learn more about Adicet’s clinical trial in lupus nephritis at https://lnkd.in/esC4winc and about the Lupus Research Alliance at https://bit.ly/LuCIN2024 #LupusAwarenessMonth #WorldLupusDay #CAR T #autoimmune #gammadelta #celltherapy
-